ÂÜÀòÂÒÂ×

Mark Bilodeau has extensive work experience in the pharmaceutical and biotechnology industry. Mark currently serves as the Chief Scientific Officer at Kestrel Therapeutics. Prior to this, they held the same position at Tarveda Therapeutics from 2019 to 2022, where they also served as the Executive Vice President of Drug Discovery from 2012 to 2022.

Before joining Tarveda Therapeutics, Bilodeau worked at Merck for over 15 years, starting in 1995. Mark held the role of Senior Director, where they managed multiple functions supporting the Neuroscience franchise and led various research projects on therapeutic targets.

Bilodeau began their career as a post-doctoral fellow at the Memorial Sloan-Kettering Cancer Center, where they focused on synthesizing complex polysaccharides and achieved the total synthesis of a human breast tumor antigen.

Mark Bilodeau received their Bachelor's Degree in Chemistry from Boston College in 1988. Mark then went on to pursue a Doctor of Philosophy (Ph.D.) in Organic Chemistry from Harvard University, completing it in 1993.